No increased risk of non-Hodgkin's lymphoma with steroids, estrogens and psyehotropies (Netherlands)

Cancer Causes and Control

Volumn 14, Issue 7, 2003, Pages 639-644

  Beiderbeck, Annette B ^a,b   Holly, Elizabeth A ^c   Sturkenboom, Miriam C J M ^b   Coebergh, Jan W ^b   Stricker, Bruno H Ch ^b   Leufkens, Hubert G M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Corticosteroids; Estrogens; Non Hodgkin's lymphoma; Pharmaco epidemiology; Psychotropics

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CORTICOSTEROID; ESTROGEN; PROTECTIVE AGENT; PSYCHOTROPIC AGENT;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; HOSPITAL DISCHARGE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NETHERLANDS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REGISTRATION;

ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; ESTROGENS; FEMALE; HUMANS; LOGISTIC MODELS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NETHERLANDS; PHARMACOEPIDEMIOLOGY; PSYCHOTROPIC DRUGS; RISK FACTORS;

EID: 0141528670     PISSN: 09575243     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025698109991     Document Type: Article

References (38)

1. Weissinger F, Kreipe HH, Wilhelm M (1997) Non-Hodgkin lymphomas. Internist (Berlin) 38: 1131-1142.
2. Cartwright R, Brincker H, Carli PM, et al. (1999) The rise in incidence of lymphomas in Europe 1985-1992. Eur J Cancer 35: 627-633.
3. Armenian HK, Hoorer DR, Rubb S, et al. (1996) Risk Factors for non-Hodgkin's lymphomas in acquired immunodeficiency syndrome (AIDS). Am J Epidemiol 143: 374-379.
4. Hoover R, Fraumeni JF, Jr. (1973) Risk of cancer in renal-transplant recipients. Lancet 2: 55-57.
5. List AF, Greer JP, Cousar JB, et al. (1986) Non-Hodgkin's lymphoma after treatment of Hodgkin's disease: association with Epstein-Barr virus. Ann Intern Med 105: 668-673.
6. Opelz G, Henderson R (1993) Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 342: 1514-1516.
7. Olsen JH, Schulgen G, Boice JD, Jr., et al. Antiepileptic treatment and risk for hepatobiliary cancer and malignant lymphoma. Cancer Res 55: 294-297.
8. Boffetta P, Kaldor JM (1994) Secondary malignancies following cancer chemotherapy. Acta Oncol 33: 591-598.
9. Hardell L, Lindstrom G, van Bavel B, Fredrikson M, Liljegren G (1998) Some aspects of the etiology of non-Hodgkin's lymphoma. Environ Health Perspect 106(Suppl 2): 679-681.
10. Kinlen LJ, Sheil AG, Peto J, Doll R (1979) Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J 2: 1461-1466.
11. Schabet M (1999) Epidemiology of primary CNS lymphoma. J Neurooncol 43: 199-201.
12. Bernstein L, Ross RK (1992) Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case-control study in Los Angeles County. Cancer Res 52(Suppl): 5510s-5515s.
13. Nelson RA, Levine AM, Marks G, Bernstein L (1997) Alcohol, tobacco and recreational drug use and the risk of non-Hodgkin's lymphoma. Br J Cancer 76: 1532-1537.
14. Holly EA, Lele C (1997) Non-Hodgkin's lymphoma in HIV-positive and HIV-negative homosexual men in the San Francisco Bay Area: allergies, prior medication use, and sexual practices. J Acquir Immune Defic Syndr Hum Retrovirol 15: 211-222.
15. Lau HS, de Boer A, Beuning KS, Porsius A (1997) Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 50: 619-625.
16. Herings RM, Stricker BH, de Boer A, Bakker A, Sturmans F (1995) Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intern Med 155: 1801-1807.
17. Herings RMC (1993) The PHARMO Drug Data Base: Design and Structure. PHARMO, a record linkage system for postmarketing surveillance of prescription drugs in the Netherlands (thesis) University of Utrecht, pp. 17-32.
18. WHO (2001) http: www.whocc.nmd.no/.
19. Dupont WD (1988) Power calculations for matched case-control studies. Biometrics 44: 1157-1168.
20. Holly EA, Lele C, Bracci PM, McGrath MS (1999) Case-control study of non-Hodgkin's lymphoma among women and heterosexual men in the San Francisco Bay Area, California. Am J Epidemiol 150: 375-389.
21. Beinlich A SR, Kaufmann M, Kuhl H (2000) Relation of cell proliferation to expression of peripheral benzodiazepine receptors in human breast cancer cell lines. Biochem Pharmacol 60: 397-402.
22. Beinlich A SR, Kaufmann M, Kuhl H (1999) Specific binding of benzodiazepines to human breast cancer cell lines. Life Sci 65: 2099-2108.
23. Niles LP WJ (1999) Diazepam inhibits forskolin-stimulated adenyl cyclase activity in human tumour cells. Pharmacol Toxicol 85: 153-156.
24. Landau MWA, Zoref-Shani E, Beery E, et al. (1998) Antiproliferative and differentiating effects of benzodiazepine receptor ligands on B16 melanome cells. Biochem Pharmacol 56: 1029-1034.
25. Leal Garza CH VCG, Rojas Alvarado MA, Cortes Gutierrez EI (1998) Mutagenic activity of diazepam evaluated by in vivo cytogenetic tests. Arch Med Res 29: 285-289.
26. Urquhart JD, Black RJ, Muirhead MJ, et al. (1991) Case-control study of leukaemia and non-Hodgkin's lymphoma in children in Caithness near the Dounreay nuclear installation [published erratum appears in BMJ 1991; 302: 818]. Br Med J 302: 687-692.
27. Holly EA, Lele C, Bracci PM (1998) Hair-color products and risk for non-Hodgkin's lymphoma: a population-based study in the San Francisco bay area. Am J Public Health 88: 1767-1773.
28. Davis S (1992) Nutritional factors and the development of non-Hodgkin's lymphoma: a review of the evidence. Cancer Res 52(19 Suppl): 5492s-5495s.
29. De Stefani E, Fierro L, Barrios E, Ronco A (1998) Tobacco, alcohol, diet and risk of non-Hodgkin's lymphoma: a case-control study in Uruguay. Leuk Res 22: 445-452.
30. Doody MM, Linet MS, Glass AG, et al. (1996) Risks of non-Hodgkin's lymphoma, multiple myeloma, and leukemia associated with common medications. Epidemiology 7: 131-139.
31. Weisenburger DD (1994) Epidemiology of non-Hodgkin's lymphoma: recent findings regarding an emerging epidemic. Ann Oncol 5(Suppl 1): 19-24.
32. Colin-Jones DG, Langman MJ, Lawson DH, Vessey MP (1983) Postmarketing surveillance of the safety of cimetidine: 12 month mortality report. Br Med J (Clin Res Ed) 286: 1713-1716.
33. Harnly ME, Swan SH, Holly EA, Kelter A, Padian N (1988) Temporal trends in the incidence of non-Hodgkin's lymphoma and selected malignancies in a population with a high incidence of acquired immunodeficiency syndrome (AIDS). Am J Epidemiol 128: 261-267.
34. Siegert E, Weissbach G, Fischer R, Lauterbach I (1998) Non-Hodgkin lymphoma (NHL) as a second neoplasm occurring after neuroblastoma treatment. Med Pediatr Oncol 30: 18-21.
35. Visser O CJ, Schouten LJ, van Dijck JAAM (2001) Incidence of cancer in The Netherlands. 1997. Utrecht Dutch Association of Comprehensive Cancer Centres.
36. Maguire-Boston EK, Suman V, Jacobsen SJ, et al. (1999) Blood transfusion and risk of non-Hodgkin's lymphoma. Am J Epidemiol 149: 1113-1118.
37. Zhang SM, Giovannucci EL, Hunter DJ, et al. (2001) Vitamin supplement use and the risk of non-Hodgkin's lymphoma among women and men. Am J Epidemiol 153: 1056-1063.
38. Doll R, Kinlen L (1970) Immunosurveillance and cancer: epidemiological evidence. Br Med J 4: 420-422.